Search

Your search keyword '"Thiebaut-Bertrand A"' showing total 3 results
Start Over Author "Thiebaut-Bertrand A" Journal biology of blood and marrow transplantation
3 results on '"Thiebaut-Bertrand A"'

1. Upfront Allogeneic Stem Cell Transplantation after Reduced-Intensity/Nonmyeloablative Conditioning for Patients with Myelodysplastic Syndrome: A Study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire

Author

Damaj, Gandhi, Mohty, Mohammad, Robin, Marie, Michallet, Mauricette, Chevallier, Patrice, Beguin, Yves, Nguyen, Stephanie, Bories, Pierre, Blaise, Didier, Maillard, Natacha, Rubio, Marie Therese, Fegueux, Nathalie, Cornillon, Jerome, Clavert, Aline, Huynh, Anne, Adès, Lionel, Thiébaut-Bertrand, Anne, Hermine, Olivier, Vigouroux, Stephane, Fenaux, Pierre, Duhamel, Alain, and Yakoub-Agha, Ibrahim

Published
2014
Full Text
View/download PDF

2. Alemtuzumab for Severe Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease

Author

Raphael Itzykson, Claude Eric Bulabois, A. Thiebaut-Bertrand, Jean-Yves Cahn, Mathieu Meunier, Sylvain Carras, Fréderic Garban, and Martin Carre

Subjects
Adult, Male, medicine.medical_specialty, medicine.drug_class, medicine.medical_treatment, Graft vs Host Disease, Antineoplastic Agents, Disease, Antibodies, Monoclonal, Humanized, Gastroenterology, Young Adult, Refractory, Internal medicine, medicine, Humans, Stage (cooking), Alemtuzumab, Transplantation, Acute graft-versus-host disease, business.industry, Hematology, Allogeneic hematopoietic cell transplantation, Middle Aged, Confidence interval, Immunosuppressive drug, surgical procedures, operative, Immunology, Corticosteroid, Female, Antibody therapy, business, medicine.drug
Abstract

Acute graft-versus-host disease (aGVHD) still remains the main cause of morbidity and mortality after allogeneic stem cell transplantation. Moreover, patients who did not respond to first-line treatment with glucocorticosteroids have a very poor outcome. Some studies suggested that alemtuzumab (a humanized monoclonal antibody against the CD52 antigen) might be effective for treatment of refractory aGVHD. Here we report a single-center experience with alemtuzumab in refractory gastrointestinal aGVHD. From September 2009 to April 2012 at the Grenoble medical university center, 24 patients who had presented a refractory gastrointestinal aGVHD to corticosteroid, or after another immunosuppressive drug, were retrospectively analyzed. Most patients (n = 19) presented stage 4 gastrointestinal aGVHD. Response to treatment (either complete or partial) was observed in 15 patients (62.4%). The overall survival rate at 1 year for all patients was 33.3% (95% confidence interval [CI], 15.9% to 51.9%) and for responders, 53.3% (95% CI, 26.3% to 74.4%). Two patients died from infection, 5 patients from recurrent GVHD, and 1 from an uncontrolled post-transplant lymphoproliferative disorder.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results